In the prefrontal cortex of subjects with schizophrenia, markers of the synthesis and re-uptake of GABA appear to be selectively altered in a subset of interneurons that includes chandelier cells. Determining the effect of these disturbances in presynaptic GABA markers on inhibitory signaling requires knowledge of the status of GABA A receptors at the postsynaptic targets of chandelier cells, the axon initial segments (AIS) of pyramidal neurons. Because the α 2 subunit of the GABA A receptor is preferentially localized at pyramidal neuron AIS, we quantified α 2 subunit immunoreactive AIS in tissue sections containing prefrontal cortex area 46 from 14 matched triads of subjects with schizophrenia, subjects with major depression and control subjects. Systematic, random sampling revealed that the mean number of α 2 -labeled AIS per mm 2 in subjects with schizophrenia was significantly (P = 0.007) increased by 113% compared to control subjects and non-significantly increased compared to subjects with major depression. Furthermore, within subjects with schizophrenia, the density of α 2 -labeled AIS was negatively correlated (r = -0.49, P = 0.038) with the density of chandelier axon terminals immunoreactive for the GABA membrane transporter. These data suggest that GABA A receptors are up-regulated at pyramidal neuron AIS in response to deficient GABA neurotransmission at chandelier axon terminals in schizophrenia. Thus, disturbances in inhibition at the chandelier neuron-pyramidal neuron synapse may be a critical component of prefrontal cortical dysfunction in schizophrenia.
Introduction
The most persistent and debilitating features of schizophrenia involve disturbances in cognitive abilities, such as working memory, which appear to ref lect dysfunction of the dorsal prefrontal cortex (PFC) (Weinberger et al., 1986; Goldman-Rakic, 1994) . This dysfunction may be associated with alterations in the inhibitory circuitry of the PFC. For example, in post-mortem studies of schizophrenia, genes responsible for the synthesis of GA BA, glutamic acid decarboxylase (GA D67), and for the re-uptake of GABA into the nerve terminal, GABA membrane transporter (GAT-1), show decreased mRNA expression in the PFC and these alterations are restricted to a subset of inhibitory neurons (Akbarian et al., 1995a; Guidotti et al., 2000; Volk et al., 2000 Volk et al., , 2001 . The affected subset of GABA neurons appears to include chandelier cells, since decreased expression of GAT-1 mRNA is associated with decreased GAT-1 protein immunoreactivity selectively in the axon terminals of chandelier neurons (Woo et al., 1998; Pierri et al., 1999) (Fig. 1E) .
The axons of chandelier cells form vertical arrays of terminals, termed 'cartridges' (Lewis and Lund, 1990) , which synapse at the axon initial segments (A IS) of pyramidal neurons (Somogyi, 1977; Freund et al., 1983; Peters, 1984) . The localization of these synapses near the site of action potential generation suggests that chandelier cells are positioned to regulate powerfully the output of pyramidal neurons. However, it remains to be determined whether a reduction in GAT-1 in chandelier axon cartridges is actually associated with altered inhibitory neurotransmission at the A IS of pyramidal neurons in schizophrenia.
The status of GABA activity at the A IS of pyramidal neurons may be further informed by an analysis of postsynaptic GABA A receptors at the A IS. Indeed, compensatory changes in GABA A receptors in response to alterations in extracellular GA BA levels have been previously reported (Montpied et al., 1991a; Mhatre and Ticku, 1994) . However, previous radioligand binding and mRNA expression studies of PFC GABA A receptors in schizophrenia (Hanada et al., 1987; Akbarian et al., 1995b; Benes et al., 1996; Huntsman et al., 1998; Impagnatiello et al., 1998; Dean et al., 1999; Ohnuma et al., 1999) have not selectively analyzed the pyramidal neuron A IS.
GABA A receptors are composed of pentamers of subunits, most commonly including at least one of each of the α, β and γ subunit classes . In addition, the different GABA A receptor α subunits have distinctive subcellular distributions (Fritschy and Mohler, 1995) . For example, in the superficial layers of human cerebral cortex, the α 2 subunit is prominently localized at pyramidal neuron A IS (Loup et al., 1998) . Indeed, although associated with only ∼15% of all GABA A receptors in the cortex (Fritschy and Mohler, 1995) , the α 2 subunit is found at >80% of inhibitory synapses onto pyramidal neuron A IS, at least in rat hippocampus (Nusser et al., 1996; Nyíri et al., 2001) . Furthermore, only 0.1% of all GABA synapses are found at pyramidal A IS, whereas nearly 25% of all α 2 -immunoreactive synapses are found at pyramidal A IS. Finally, GABA A receptors containing the α 2 subunit have a higher affinity for GABA and faster activation and slower de-activation times, compared to GABA A receptors containing the more commonly expressed α 1 subunit (Levitan et al., 1988; Lavoie et al., 1997) . Thus, GABA A receptors containing the α 2 subunit appear to be anatomically positioned and functionally adapted to mediate a potent inhibitory inf luence on the output of pyramidal neurons and, thus, may provide critical insight into the status of inhibitory activity at pyramidal neuron A IS.
Therefore, we examined human post-mortem brain tissue containing PFC area 46 in order to determine: (i) whether the density of pyramidal neuron A IS immunoreactive for the GABA A receptor α 2 subunit (α 2 -A IS) is altered in subjects with schizophrenia; (ii) whether changes in α 2 -AIS density are specific to the diagnosis of schizophrenia; and (iii) whether α 2 -A IS density is related to presynaptic GA BA markers in chandelier axon cartridges in subjects with schizophrenia.
Materials and Methods

Characteristics of Study Subjects
Brain specimens were obtained during autopsies conducted at the A llegheny County Coroner's Office after obtaining consent from the surviving next of kin. The 14 triads of subjects used in this study each consisted of one subject with schizophrenia matched to one control subject and one subject with major depressive disorder (MDD) for sex, and as closely as possible for age and post-mortem interval (PMI; Table 1) . A ll subjects with schizophrenia, all control subjects and all but five subjects with MDD (613, 689, 693, 698 and 803;  Table 1) were included in previous studies of chandelier axon cartridges immunoreactive for GAT-1 -'GAT-1-cartridges' (Woo et al., 1998; Pierri et al., 1999) . All subjects were under the age of 70 years and all subjects with schizophrenia were previously determined to have at least a 10% decrease in the density of GAT-1-cartridges compared to matched control subjects.
An independent panel of experienced clinicians arrived at consensus DSM-III-R diagnoses after reviewing medical records and/or the results of structured interviews conducted following written, informed consent with family members of the deceased (Glantz and Lewis, 1997) . No psychiatric disorders were present in the control subjects. Six schizophrenic subjects and nine subjects with MDD had a history of an alcohol and/or substance abuse disorder (Table 1 ). Four schizophrenic subjects had been off antipsychotic medications prior to death (234, neurolepticnaïve; 450, discontinued for unknown length of time; 537, 10 months; 622, 7 months; Table 1 ) and two subjects with MDD were on antipsychotic medications at time of death. Three schizophrenic subjects and four subjects with MDD were receiving benzodiazepines at time of death. The mean (±SD) ages of the subjects with schizophrenia and MDD at the onset of illness were 29.7 ± 9.4 and 41.6 ± 10.7 years, respectively, and the average durations of illness were 23.3 ± 8.4 and 11.7 ± 9.3 years, respectively. A ll procedures were approved by the University of Pittsburgh's Institutional Review Board for Biomedical Research.
Tissue Processing
Upon retrieval, brain specimens were blocked coronally, placed into 4% paraformaldehyde for 48 h, cr yoprotected and then stored at -30°C. Subject groups did not significantly differ in mean storage time [F(2,42) = 2.36, P = 0.11; Table 1 ]. Blocks containing the left middle frontal gyrus were sectioned coronally at 40 µm on a calibrated cryostat. Nissl-stained sections were used to identif y PFC area 46 in each subject using cytoarchitectonic criteria (Daviss and Lewis, 1995; Rajkowska and Goldman-Rakic, 1995) . Neuropathological examination of each brain revealed no abnormalities in the region of interest and A lzheimer's disease was ruled out in each subject using clinical and neuropathological criteria.
Four tissue sections containing PFC area 46, in serial order and ∼400 µm apart, from each subject were processed in a randomized block design (i.e. with one section from each subject in a triad always processed together, and with different combinations of triads in each run). Using an antibody raised in guinea pig against the cDNA-derived N-terminal sequence (amino acid residues 1-9) of the human GABAA receptor α2 subunit (Marksitzer et al., 1993) , sections were processed using the avidin-biotin procedure, followed by diaminobenzidine and hydrogen peroxide as previously described (Woo et al., 1998) . Reaction product was intensified through serial immersions in aqueous osmium tetroxide and thiocarbohydrizide, followed by silver nitrate and gold chloride (Pucak et al., 1996) .
The specificity of the antibody for the GABAA receptor α2 subunit was previously demonstrated by Western blot experiments whereby immunoprecipitation of GABAA receptor α2 subunit by the antibody revealed a single band whose signal intensity was reduced in a dose-dependent manner following preadsorption with increasing concentrations of GA BAA receptor α2 subunit peptide (Marksitzer et al., 1993) . Specificity was also confirmed by anatomical observations described in the Results section.
Quantification
All quantification was conducted by one rater (D.W.V.), who was blinded to diagnosis and subject number. Using the Stereo Investigator fractionator program (MicroBrightField Inc., Colchester, VT), a region of the middle frontal gyrus containing area 46 and of uniform cortical depth was sampled in each subject. Using a 5× objective, a contour containing layers 2-3a, defined as 25% of the total cortical width immediately below the layer 1-2 border, was drawn on each section (mean ± SD total contour area per subject: 10.7 ± 2.6 mm 2 ). This zone was chosen because it contains ∼80% of the total number of α 2 -A IS in the PFC and in order to maintain consistency with a previous study on the density of GAT-1-cartridges in this laminar location in the same cohort of subjects (Pierri et al., 1999) . Between 40 and 50 counting frames, 70 × 70 µm, were systematically and randomly placed within the contour for each tissue section and two sides of each counting frame were identified as exclusion boundaries. Using a 100× oil-immersion objective (NA 1.4), all α 2 -A IS (see Results for criteria) within each counting frame were identified on a video monitor at a final magnification of 2450×. The total number of α 2 -AIS counted in each subject ranged from 4 to 616 and the mean (±SD) coefficient of error for α 2 -AIS counts per sampling frame in each subject was 0.13 ± 0.08. Assessments of intra-rater reliability in identifying α 2 -AIS throughout the course of the quantification procedure revealed an intraclass correlation coefficient of 0.99 (95% CI = 0.59-1.0).
In a separate analysis using the Neurolucida program (MicroBrightField Inc., Colchester, VT), mean length of α2-AIS was also determined in each schizophrenic and control subject. In one random tissue section from each subject, the length of every detectable α2-AIS was measured in a series of 100 µm wide cortical traverses. The average (±SD) number of α2-AIS measured in each subject was 54 ± 21.
Statistical Analysis
Measures of the density of α 2 -A IS per mm 2 in each of the four tissue sections for each subject were treated as four correlated observations. A multivariate analysis of covariance (M A NCOVA) model assuming a compound symmetric covariance structure (Neter et al., 1996) was employed to test for a main effect of diagnosis, with triad and immunohistochemistry run included as blocking factors and tissue storage time as a covariate. In this model, the inclusion of triad accounted for matching of subjects for sex, age and PMI. Because regression analyses revealed a potential effect of PMI on α 2 -A IS density, two additional MANCOVA models were run. One model included both diagnosis and triad factors, with PMI and tissue storage time as covariates and run as a blocking factor; the other model included a diagnosis factor with sex, age, PMI and tissue storage time as covariates, and run as a blocking factor. As all three models yielded similar results, only the results of the primary model are reported. Comparisons between any two of the diagnostic groups were also conducted using the primary model. In addition, the effects of sex, psychotropic medication at time of death and/or alcoholism on α 2 -AIS density in subjects with schizophrenia were assessed using ANCOVAs with the difference in α 2 -A IS density within matched pairs of schizophrenic and control subjects as the dependent variable and PMI as a covariate. Finally, a one-tailed Pearson correlation was used to test the hypothesis that GAT-1-cartridge density was inversely related to α 2 -AIS density in subjects with schizophrenia. Analyses were implemented in SAS PROC Mixed (Littell et al., 1996) and all statistical tests were conducted with α = 0.05.
Results
Immunoreactivity for the GABAA Receptor α2 Subunit in Human PFC As shown in Figure 1A , immunoreactivity for the GABAA receptor α2 subunit in human PFC was greatest in the supragranular layers, particularly in layer 2. This pattern directly parallels previous reports of α2-immunoreactivity in the medial PFC of rat (Dunn et al., 1996) and of α2 mRNA expression in human PFC (Akbarian et al., 1995b) . At higher magnification, α2 subunit-immunoreactivity was prominently found in pyramidal neuron A IS -α2-AIS (Nusser et al., 1996; Loup et al., 1998; Nyíri et al., 2001 ) -identified as intensely immunoreactive, discrete, non-branching, vertically oriented processes located below unlabeled cell bodies, ranging in length from 8 to 40 µm and usually slightly tapered from superficial to deep (Figure 1B-D) .
α2-AIS Density in Schizophrenia and Major Depression
Statistical analysis using the primary M ANCOVA model revealed a significant main effect of diagnosis [F(2,25) = 4.88, P = 0.016] on α2-A IS density. The mean (±SD) number of α2-AIS per mm 2 was significantly [F(1,12) = 10.60, P = 0.007] increased by 113% in subjects with schizophrenia (302 ± 184) compared to control subjects (141 ± 119). Furthermore, in 12 of the 14 matched pairs of schizophrenic and control subjects, α2-A IS density was higher in the schizophrenic subject (Fig. 2) . As illustrated in Figure 3 , the mean increase in α2-A IS density in individual subjects with schizophrenia compared to their matched controls did not significantly differ when the subjects with schizophrenia were subdivided into groups based on gender [F(1,11) = 0.007, P = 0.934], treatment with psychotropic medications at time of death [F(1,11) = 0.201, P = 0.663], or histor y of an alcoholrelated disorder [F(1,11) = 0.002, P = 0.968]. In addition, mean α2-A IS density was virtually identical in the three subjects with schizoaffective disorder (295 ± 203) and the 11 subjects with 'pure' schizophrenia (304 ± 189; Fig. 4) .
In contrast to the group differences in α 2 -AIS density, mean α 2 -A IS length (in µm) was similar in both schizophrenic and control subjects (14.8 ± 5.6 and 14.7 ± 5.2, respectively). However, α 2 -A IS length was positively correlated with α 2 -A IS density in subjects with schizophrenia (r = 0.548, P = 0.042), but not in control subjects (r = 0.124, P = 0.674).
The mean density of α 2 -A IS was also increased in the subjects with schizophrenia by 37% compared to subjects with MDD (Fig. 2) . Although this difference was not statistically significant [F(1,12) = 1.68, P = 0.22], 10 of the 14 subjects with schizophrenia had an increased density of α 2 -A IS compared to the matched subject with MDD. Furthermore, one subject with MDD (689; Table 1) appeared to be an outlier in that the density of α 2 -A IS in this subject (α 2 -A IS/mm 2 = 731) was 2.6 SD above the mean α 2 -A IS density for all subjects with MDD (Fig. 2) . Consequently, this outlier subject was included in the main statistical analysis, but excluded from subsequent analyses in which diagnosis groups were subdivided into smaller groups on the basis of demographic variables. Importantly, no demographic variable, such as psychotropic medication at time of death, history of alcoholism, presence of psychotic features, tissue storage time, or PMI, appeared to contribute to the increased α 2 -A IS density in this subject, or any other subject. When triad 9, which included subject 689, was excluded from analysis, the mean density of α 2 -A IS in subjects with schizophrenia was increased by 59% compared to subjects with MDD [182 ± 138, F(1,11) = 2.86, P = 0.12]. Furthermore, mean α 2 -A IS density did not significantly differ between control subjects and subjects with MDD [F(1,11) = 0.53, P = 0.48]. Finally, mean α 2 -A IS density in the four subjects with MDD with psychotic features did not differ from either the MDD subjects without psychotic features or the control subjects (Fig. 4) .
Reciprocal Changes in α2-A IS and GAT-1-Cartridge Density in Schizophrenia
The density of GAT-1-cartridges in area 46 was previously determined for all subjects with schizophrenia, all control subjects and nine subjects with MDD examined in the present study (Woo et al., 1998; Pierri et al., 1999) . Whereas the mean α2-AIS density in the subjects with schizophrenia was approximately twice that in the matched control subjects, the mean GAT-1-cartridge density in the same schizophrenic subjects was less than half that in the matched control subjects (Fig. 5) . Furthermore, a significant inverse relationship (r = -0.49, P = 0.038) between the densities of α2-AIS and GAT-1-cartridges was present in the subjects with schizophrenia. In contrast, in the nine subjects with MDD included in the previous GAT-1-cartridge study, neither the mean density of α2-AIS nor of GAT-1-cartridges differed significantly from the nine matched control subjects (Fig. 5) .
Discussion
In this study, α2-A IS density in the superficial PFC layers of subjects with schizophrenia was significantly increased compared to control subjects and was also increased, though nonsignificantly, compared to subjects with MDD. Furthermore, α2-AIS density was inversely related to GAT-1-cartridge density in subjects with schizophrenia. These data suggest that presynaptic alterations in chandelier neurons are associated with postsynaptic changes in GABAA receptors at the A IS of pyramidal neurons in schizophrenia.
Specificity of Findings for Schizophrenia
The increase in α2-A IS density appears to be relatively specific to the diagnosis of schizophrenia, or at least not a common feature of MDD, even when that disorder is accompanied by psychosis. Consistent with these findings, previous studies of the frontal cortex in subjects with MDD have failed to find differences in the concentration, synthesis, or re-uptake of GABA (Cheetham et al., 1988; Korpi et al., 1988; Sundman et al., 1997) . Thus, alterations in PFC GABA neurotransmission at the chandelier cell-pyramidal neuron synapse appear to be a characteristic of schizophrenia that is not associated with depression or psychosis, per se.
Several lines of evidence suggest that treatment with antipsychotic medications and benzodiazepines or a history of alcoholism do not account for the changes in PFC GA BA markers in subjects with schizophrenia. First, α 2 -A IS density was . Bar graphs showing the mean (±SD) number of α 2 -AIS per mm 2 in control subjects, subjects with major depressive disorder grouped by the absence (MDD) or presence (MDD + P) of psychotic features, subjects with schizoaffective disorder (SA) and subjects with 'pure' schizophrenia (SCH). *One subject with MDD, 689, was determined to be an outlier (see Results) and, consequently, was not included in this figure.
Figure 5. Bar graph showing the percentage change in the mean densities of α 2 -AIS (solid bars) and GAT-1-cartridges (cross-hatched bars) in schizophrenic subjects (left) and in subjects with MDD (right) compared to the matched control subjects. The percentage changes in α 2 -AIS and GAT-1-cartridge densities in MDD were calculated from the nine subjects with MDD and the nine matched control subjects for whom GAT-1-cartridge densities were available.
increased in subjects with schizophrenia, regardless of the use of psychotropic medications at time of death or history of an alcohol-related disorder. Consistent with these obser vations, studies of haloperidol-treated monkeys revealed no changes in the expression of GA D 67 or GAT-1 mRNAs or the density of GAT-1-cartridges in the PFC (Pierri et al., 1999; Volk et al., 2000 Volk et al., , 2001 . In addition, pharmacological manipulations in rats have found that: (i) antipsychotic medications result in decreased muscimol binding to GABA A receptors (Johnson et al., 1994; Farnbach-Pralong et al., 1998) ; (ii) benzodiazepine treatment causes no changes in cortical GABA A receptor α 2 subunit mRNA or protein expression levels (O'Donovan et al., 1992; Holt et al., 1996 Holt et al., , 1997 Impagnatiello et al., 1996; Chen et al., 1999; Tietz et al., 1999) ; and (iii) ethanol results in either decreases or no change in cortical GA BA A receptor α 2 mRNA expression (Montpied et al., 1991b; Mhatre et al., 1993; Chen et al., 1998) 
Methodological Considerations
The stereological principle of systematic, random sampling was employed in this study to reduce sampling bias; however, the lack of clear boundaries of PFC area 46 precluded the determination of the total number of α2-A IS in this region. Importantly, measures of α2-A IS density were not confounded by differences in α2-A IS length between the schizophrenic and control groups. Furthermore, given that α2-A IS and GAT-1-cartridge densities were changed in opposite directions in nearby tissue sections from the same subjects with schizophrenia, neither the method of quantification nor potential differences in cortical volume across subject groups appear to have introduced a systematic confound.
We interpret the greater density of α 2 -A IS in schizophrenia as ref lecting an increase in the amount of α 2 subunit and the total density of GA BA A receptors, per A IS, resulting in a greater number of A IS with detectable levels of immunoreactivity. Unfortunately, direct quantification of GABA A receptor subunits in pyramidal neuron A IS would require the use of proceduresfor example immunogold-labeling and electron microscopy or immunof luorescence at the light microscopic level (Sutoo et al., 1998) -that are technically challenging in post-mortem human brain. However, it seems unlikely that the increased α 2 -AIS density ref lects an increase in pyramidal neuron density. First, in previous studies, PFC neuron density was reported to be either unchanged (Akbarian et al., 1995a) , or, at ∼20%, not increased enough (Selemon et al., 1995 in schizophrenia to account for the present findings. Second, in the same subjects examined in the present study, the density of GAT-1-cartridges was actually reduced by >50%, which further argues against an increase in pyramidal neuron density. Finally, re-analysis of data from a previous study revealed no difference in deep layer 3 pyramidal neuron density between the same cohort of subjects with schizophrenia (48.4 ± 7.7 cells/0.001 mm 3 ) and control subjects (49.1 ± 8.7 cells/0.001 mm 3 ) examined in the present study.
Alternatively, an increased amount of α 2 subunit at the A IS could be coupled with reductions in other subunits reported to be located at pyramidal neuron A IS, such as the α 1 and α 3 subunits (Nusser et al., 1996; Loup et al., 1998) , without changes in the total number of GABA A receptors. Such 'subunit switching' between the α 2 and α 1 subunits occurs in rat hypothalamic oxytocin neurons during pregnancy (Brussaard and Herbison, 2000) . Unfortunately, quantification of α 1 -labeled A IS in schizophrenia is not possible, since the much greater density of α 1 subunit at other locations (Nusser et al., 1996) prohibits the resolution of α 1 -labeled A IS by light microscopy. In addition, we were not able to detect α 3 -immunoreactivity in pyramidal neuron A IS in our human tissue samples. Yet, even if 'subunit switching', without a change in total receptor number, occurs in schizophrenia, an increased proportion of GA BA A receptors containing the α 2 subunit would still likely confer a greater inhibitory response to GABA at pyramidal neuron A IS (Levitan et al., 1988; Lavoie et al., 1997) . Thus, the increase in α 2 -A IS density, whether ref lecting an increased total density of GABA A receptors or an increased proportion of GA BA A receptors containing the α 2 subunit, suggests that postsynaptic GA BA A receptors at pyramidal neuron A IS are functionally up-regulated in schizophrenia.
Pathophysiological Significance
The inverse relationship between the densities of α2-A IS and GAT-1-cartridges in the same subjects with schizophrenia suggests that GA BAA receptors are up-regulated at pyramidal neuron A IS in response to deficient GA BA activity in chandelier axon terminals in schizophrenia (Fig. 6) . Although experimental models of a selective decrease in GA BA release at chandelier axon terminals are not available, previous studies (Mhatre and Ticku, 1994) have demonstrated that GA BAA receptor antagonists produce increased α2 subunit mRNA expression in embr yonic chick neurons. Furthermore, in subjects with temporal lobe epilepsy, a loss of GA BA neurons is associated with a substantial increase in α2 subunit immunoreactivity in pyramidal cells (Loup et al., 2000) .
The mRNA expression for presynaptic inhibitory markers, including GAD 67 and GAT-1, is decreased in the PFC of subjects Figure 6 . Alterations in GABA neurotransmission at the chandelier neuron-pyramidal neuron synapse in schizophrenia. In a subset of GABA neurons that appears to include chandelier neurons (pink), the mRNA expression for GAD 67 and GAT-1 are both reduced below a detectable level (Volk et al., 2000 ) and the protein level of GAT-1 is selectively reduced in chandelier neuron axon terminals (Woo et al., 1998; Pierri et al., 1999) , which synapse at the AIS of pyramidal neurons. In postsynaptic pyramidal neurons (blue), immunoreactivity for the GABA A receptor α 2 subunit is increased at the axon initial segment (light blue), suggesting that GABA A receptors are up-regulated in response to a reduction in inhibitory neurotransmission in chandelier neuron axon terminals.
with schizophrenia (Akbarian et al., 1995a; Ohnuma et al., 1999; Guidotti et al., 2000; Volk et al., 2000 Volk et al., , 2001 . In contrast, mRNA levels of the major postsynaptic GABA A receptor subunits appear to be unchanged in schizophrenia (Akbarian et al., 1995b) , although some studies have reported increases in the α 1 subunit (Impagnatiello et al., 1998; Ohnuma et al., 1999) and a reduction in the short isoform of the γ 2 subunit (Huntsman et al., 1998) . Of particular interest, α 2 subunit mRNA expression was unchanged in PFC area 46 of subjects with schizophrenia (Akbarian et al., 1995b) . Although other explanations are possible, the increase in α 2 -A IS density may ref lect a locally regulated increase in α 2 subunit at pyramidal neuron A IS. However, alterations in α 2 -immunoreactivity at locations other than the A IS, such as pyramidal neuron soma (Nyíri et al., 2001) , cannot be excluded. Furthermore, radiolabeled ligand binding studies of PFC GA BA A receptors have revealed increases in muscimol binding (Hanada et al., 1987; Benes et al., 1996; Dean et al., 1999) that were most prominent at pyramidal neuron soma (Benes et al., 1996) . Together, these data suggest that GABA A receptors located at the soma and A IS of pyramidal neurons are locally up-regulated in schizophrenia in response to a reduction in proximal inhibitory input.
The pathophysiological mechanism that selectively initiates disturbances in a subset of GA BA neurons that appears to include chandelier neurons, but not in the majority of PFC GABA neurons (Woo et al., 1998; Volk et al., 2000 Volk et al., , 2001 , remains unclear. One possibility is that reduced inhibitory neurotransmission in chandelier neurons ref lects an abnormality intrinsic to this cell class. Alternatively, inhibitory neurotransmission may be reduced in chandelier neurons in response to an alteration in their excitatory inputs. For example, morphological alterations in layer 3 pyramidal neurons in PFC area 46 (Garey et al., 1998; Rajkowska et al., 1998; Glantz and Lewis, 2000; Pierri et al., 2001 ) and reduced neuronal number in the mediodorsal thalamic nucleus (Pakkenberg, 1990; Popken et al., 2000; Young et al., 2000; Byne et al., 2002) have been reported in subjects with schizophrenia. Interestingly, in monkey PFC area 46, the dendrites of parvalbumin-containing cells, which include chandelier neurons, receive synaptic inputs from local pyramidal neurons (Melchitzky et al., 2001) and from the mediodorsal thalamic nucleus (Melchitzky et al., 1999) , whereas other classes of GABA cells do not (Melchitzky and Lewis, 2000) . Further studies of the mechanism(s) responsible for altered chandelier-cell-pyramidal-neuron inhibitory neurotransmission may lead to novel therapeutic strategies for remediating prefrontal cortical dysfunction in schizophrenia.
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